Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer
Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer
Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer.
Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
85
Ans
Genre
Femme
Aire thérapeutique :
Oncologie
Maladie :
Cancer du sein métastatique
Traitement :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Date de début de l'étude :
04 Octobre 2012
End date :
05 Septembre 2018
Identifiant de l'essai :
PM0259 CA 231 B0
Identifiant EudraCT/CTIS :
2012-003530-16
Envoyer par email